Antibody Vaccines Market Trends
Category Intelligence on Antibody Vaccines covers the following
- Information relating to market, supply, cost, and pricing analysis
- Hard to find data on cost and TCO models, supplier details, and performance benchmarks
- Macroeconomic and regional trends impacting cost, supply, and other market dynamics
- Category-specific negotiation and sourcing advice
Industry Outlook & Drivers
Antibody Vaccines Global Market Outlook:
Market Growth: CAGR growth rate: $3.28 Billion in 2018 and expected to reach $4.19 Billion by 2022, growing at a CARG of 6.2 percent
Reduction in availability of targeted researchers and physician is expected, due to outbreak of COVID, which is impacting the antibody vaccine
development and analytical testing services
Due to the COVID breakdown, demand for developing antibody vaccine for novel coronavirus is increasing and hence, pharmaceutical
companies are collaborating with research institutions to enhance the speed of antibody vaccine development
Porter's Analysis on Antibody Vaccines
- Supplier power is medium as most of the buyers enter into strategic relationships with the preferred suppliers
- Most of the buyers have particular set of suppliers to be considered for the development process. This is based upon the various technologies and
Barriers to New Entrants
- Set up and scale up of mammalian cell cultures require time.
- Buyers prefer to go for strategic relationships in this category. Suppliers currently existing in the market have working relationships with various buyers and the entry of a new entrant would be difficult.
Intensity of Rivalry
- The rivalry faced by the CMOs is not from the direct competitors, but rather an influx of capacity from the players who were product manufacturers earlier.
- The differences in the established volume, processes, technologies differentiates the various suppliers in the supply space.
- The CMO space is growing at a rate greater than the increase in demand.
Threat of Substitutes
- Monoclonal antibodies operate by mimicking the natural defense mechanism of the human body, and is really effective the areas of Cancer and auto immune diseases.
- Unless a new technology/process can find an alternative for the treatment, the threat of substitute is really low.
The utilization rates of the supplier facilities are expected to drop going foreword as the suppliers and buyers are expanding at a rate higher than the
increase in supply.
Most of the buyers outsource high volumes to a supplier often leading to the allotment of a dedicated space.